Most potency loss from heat exposure is invisible
GLP-1s can help people with type 2 diabetes, obesity, and overweight
Current research has not established significant hormone-related side effects specific to women
However, Epithalon remains investigational with no FDA approval, most research conducted in Russia with limited Western replication, long-term human safety data sparse, optimal dosing protocols still debated, and mechanisms not fully understood
Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing significant effects on body weight and blood glucose
Dosing Schedule Oral semaglutide is taken daily, ideally in the morning on an empty stomach